Pharmac responds to our feedback we submitted in April following PTAC’s recommendation that erenumab be funded, but with a low priority.
Last week we received a reply from Pharmac regarding the feedback we submitted following the Pharmacology and Therapeutics Advisory Committee (PTAC) recommendation that erenumab (Aimovig) be funded, but with a low priority and only for patients with chronic migraine.
Pharmac has advised us that it intends to take our submission to PTAC for consideration at a future meeting. There are only two more meetings scheduled for 2022 and the 2023 meeting dates are yet to be released.
The funding of erenumab is now under assessment by Pharmac, using its Factors for Consideration framework, and includes additional information in its decision making. We are optimistic that our feedback will be included in any decisions Pharmac make, and we will keep our migraine community updated with any progress.
This is just one step we as an organisation are taking to support access and funding of CGRP monoclonal antibody medications in Aotearoa New Zealand.